ACCORD – a Phase 2, clinical trial platform designed to rapidly test candidate drugs for the treatment of COVID-19 – has completed patient recruitment for the first of its arms.
The ongoing study is delivered in collaboration with the Medicines Evaluation Unit in Manchester and NHS hospital sites across the UK, supported by the NIHR. ACCORD is led by Professor Tom Wilkinson at the NIHR Southampton Biomedical Research Centre.
ACCORD’s work evaluating new candidate drugs for large scale trials is vital, with only limited treatment options for those who are hospitalised with COVID-19. Despite vaccine programmes helping to reduce COVID-19 cases and incidence of severe COVID-19, new treatments will remain critical to improving outcomes for hospitalised patients and reducing pressure on intensive care units.
Analysis of the full dataset from ACCORD is expected to be completed in the next few months following completion of patient recruitment in the additional two arms.
Comments